vgn-r09b
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 30, 2023 (NCT05765981)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DOPA decarboxylaseSupplementation
supplementation - AADC
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06480461 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | Shanghai Vitalgen BioPharma Co., Ltd. |
| NCT06432140 | Phase 1 | May 31, 2024 | Jiao Tong University, Shanghai Vitalgen BioPharma Co., Ltd. |
| NCT05765981 | Early Phase 1 (Phase 1) | Jan 30, 2023 | Jiao Tong University, Shanghai Vitalgen BioPharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Vitalgen BioPharma Co., Ltd. | For profit | 3 | 2 | 2 | 2023 |
| Jiao Tong University | Academic/Hospital | 2 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1